ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Concalls
Every earnings call, live and summarised
Earnings calls
Every Healthcare Global Enterprises earnings call we streamed: the live audio and our summary of what management said.
Q2 revenue ₹732 Cr, +16% YoY; H1 ₹1,410 Cr, +15%. EBITDA margin 19.7% despite ~₹6 Cr wage-revision hit. Trade-margin cap guided at mid-to-high single-digit annualised impact, with few specifics.
Q2 revenue ₹732 Cr, +16% YoY; H1 ₹1,410 Cr, +15%. EBITDA margin 19.7% despite ~₹6 Cr wage-revision hit. Trade-margin cap guided at mid-to-high single-digit annualised impact, with few specifics.
Guidance: mid-teens revenue, high-teens EBITDA growth through FY29; tax 35-40% near term.
HCG reported a strong Q1FY27 with 13% YoY revenue growth and 20% EBITDA growth, driven by volume and improved payor mix.
HCG delivered strong FY26 performance with 15% revenue growth and margin expansion. Strategy focuses on oncology core through the sale of fertility unit Milann and brownfield expansion.
HCG delivered strong FY26 results with 15% revenue growth and margin expansion to 18.5%, driven by operational leverage and clinical excellence.
HCG reported FY26 revenue of INR 25.4bn (up 15% YoY) and Adj. EBITDA of INR 4.7bn (up 19% YoY), driven by network productivity and operational leverage.
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.